期刊文献+

华法林抗凝国际标准化比值用药管理软件的开发

下载PDF
导出
摘要 华法林是一种临床应用较为广泛的口服抗凝药物,因其有疗效确切、作用时间长及价格低廉等优点,被广泛用于人工心脏瓣膜置换术后、房颤、脑卒中等疾病的长期抗凝治疗和预防。华法林的血药浓度易受遗传、年龄、食物、合并疾病、联合用药等诸多因素影响[1],导致国际标准化比值(INR)升高或降低。华法林剂量个体差异大,需个体化调整,且会根据患者饮食等诸多原因,随时发生变化。
作者 张伟 裴妍艳
出处 《中国乡村医药》 2021年第14期35-36,共2页
  • 相关文献

参考文献2

二级参考文献31

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1401
  • 2WOLF P, ABBOTT RD, KANNEL WB. Atrial fibrillation as an independent risk factor for stroke: the framingham study [ J ]. Stroke, 1991, 22(8) : 983 -988.
  • 3CONNOLLY SJ, EZEKOWITZ MD, YUSUF S, et al. Dablgat- ran versus warfarin in patients with atrial fibrillation[ J]. N Engl JMed, 2009, 361(12): 1139 -1151.
  • 4PATEL MR, MAHAFFEY KW, GARG J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [ J ]. N Engl J Med, 2011, 365(10): 883-891.
  • 5WHO. Choosing Interventions that arc Cost Effective ( WHO- CHOICE) , Threshold values for intervention cost-effectiveness by Region[ EB/OL]. 2010[2016 -01 -29]. http://www, who. int/choice/costs/CER_levels/en/.
  • 6KREJCZY M, HARENBERG J, MARX S, et al. Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and aplxaban in patients with non-valvular atrial fibrillation across countries[J]. J Thromb Thrombolysis, 2014, 37 (4) : 507 - 523.
  • 7WISLOFFT, HAGEN G, KLEMPM. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke pre- vention in atrial fibrillation( J ]. Pharmacoeconomics, 2014, 32 (6) : 601 -612.
  • 8CHANG CH, YANG YHK, CHEN JH, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan [ J] Thrombosis Res, 2014, 133(5) : 782 -789.
  • 9CHANG CH, YANG YHK, CHEN JH, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan [ J ] Thrombosis Res, 2014, 133(5) : 782 -789.
  • 10US Food and Drug Administration. Briefing information for the September 20,2010 meeting of the Cardiovascular and Renal Drugs Advisory Committee[EB/OL]. [2012 -03 - 16]. Sliver Spring (MD): FDA, 2010. Clinical review: Pradaxa (dabigat- ran). NDA 022-512. http://www, fda. gov/downloads/Advisory- Committees/CommitteesMeetingMaterials/Drugs/Cardiovascu- larandRenalDrugsAdvisoryCommittee/UC M247244. pdf.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部